ESMO 2023 | The future role of active surveillance in esophageal cancer

Berend J. Van der Wilk, MD, PhD, Erasmus University Medical Center, Rotterdam, Netherlands, comments on the implications of the SANO trial, which demonstrated the non-inferiority of active surveillance in patients with esophageal cancer. The advantages of active surveillance include avoiding esophagectomy, but additional research is needed to assess the long term effects of active surveillance. This interview took place at the European Society for Medical Oncology (ESMO) 2023 Congress in Madrid, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.